###begin article-title 0
###xml 10 18 <span type="species:ncbi:12643">Mousepox</span>
Surviving Mousepox Infection Requires the Complement System
###end article-title 0
###begin p 1
Conceived and designed the experiments: EAM JPA RMLB. Performed the experiments: EAM. Analyzed the data: EAM JPA RMLB. Contributed reagents/materials/analysis tools: EAM JPA RMLB. Wrote the paper: EAM JPA RMLB.
###end p 1
###begin p 2
###xml 539 542 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 814 817 814 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1282 1285 1282 1285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1297 1300 1297 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 127 143 <span type="species:ncbi:12643">Ectromelia virus</span>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
###xml 171 179 <span type="species:ncbi:10255">smallpox</span>
###xml 380 396 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 549 565 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 873 878 <span type="species:ncbi:10090">mouse</span>
###xml 896 912 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 1301 1305 <span type="species:ncbi:10090">mice</span>
Poxviruses subvert the host immune response by producing immunomodulatory proteins, including a complement regulatory protein. Ectromelia virus provides a mouse model for smallpox where the virus and the host's immune response have co-evolved. Using this model, our study investigated the role of the complement system during a poxvirus infection. By multiple inoculation routes, ectromelia virus caused increased mortality by 7 to 10 days post-infection in C57BL/6 mice that lack C3, the central component of the complement cascade. In C3-/- mice, ectromelia virus disseminated earlier to target organs and generated higher peak titers compared to the congenic controls. Also, increased hepatic inflammation and necrosis correlated with these higher tissue titers and likely contributed to the morbidity in the C3-/- mice. In vitro, the complement system in naive C57BL/6 mouse sera neutralized ectromelia virus, primarily through the recognition of the virion by natural antibody and activation of the classical and alternative pathways. Sera deficient in classical or alternative pathway components or antibody had reduced ability to neutralize viral particles, which likely contributed to increased viral dissemination and disease severity in vivo. The increased mortality of C4-/- or Factor B-/- mice also indicates that these two pathways of complement activation are required for survival. In summary, the complement system acts in the first few minutes, hours, and days to control this poxviral infection until the adaptive immune response can react, and loss of this system results in lethal infection.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 46 54 <span type="species:ncbi:10255">smallpox</span>
###xml 262 270 <span type="species:ncbi:10255">smallpox</span>
###xml 367 375 <span type="species:ncbi:12643">mousepox</span>
###xml 401 406 <span type="species:ncbi:9606">human</span>
###xml 407 415 <span type="species:ncbi:10255">smallpox</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 538 554 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 579 587 <span type="species:ncbi:12643">mousepox</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
###xml 762 778 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 819 835 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 1075 1079 <span type="species:ncbi:10090">mice</span>
###xml 1112 1128 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 1248 1264 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 1364 1372 <span type="species:ncbi:10255">smallpox</span>
As one of the most successful pathogens ever, smallpox caused death and disfigurement worldwide until its eradication in the 1970s. The complement system, an essential part of the innate immune response, protects against many pathogens; however, its role during smallpox infection is unclear. In this study, we investigated the importance of the complement system in mousepox infection as a model for human smallpox disease. We compared mice with and without genetic deficiencies in complement following infection by multiple routes with ectromelia virus, the causative agent of mousepox. Deficiencies in several complement proteins reduced survival of ectromelia infection. Sera from these same complement-deficient mice also have reduced ability to neutralize ectromelia virus in vitro. In complement-deficient mice, ectromelia virus disseminated from the inoculation site earlier and produced higher levels of virus in the bloodstream, spleen, and liver. The increased infection in the liver resulted in greater tissue damage. We hypothesize that the complement-deficient mice's reduced ability to neutralize ectromelia virus at the inoculation site resulted in earlier dissemination and more severe disease. We have demonstrated that surviving ectromelia virus infection requires the complement system, which suggests that this system may also protect against smallpox infection.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 300 303 300 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Henderson1">[1]</xref>
###xml 374 377 374 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Parker1">[2]</xref>
###xml 625 628 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-McFadden1">[3]</xref>
###xml 629 632 629 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Buller1">[4]</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 112 125 <span type="species:ncbi:10255">variola virus</span>
###xml 150 158 <span type="species:ncbi:10255">smallpox</span>
###xml 160 168 <span type="species:ncbi:10255">Smallpox</span>
###xml 321 336 <span type="species:ncbi:10244">monkeypox virus</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
###xml 410 418 <span type="species:ncbi:10255">smallpox</span>
###xml 473 489 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 491 495 <span type="species:ncbi:12643">ECTV</span>
###xml 521 529 <span type="species:ncbi:12643">mousepox</span>
###xml 531 544 <span type="species:ncbi:10255">Variola virus</span>
###xml 549 553 <span type="species:ncbi:12643">ECTV</span>
###xml 657 665 <span type="species:ncbi:12643">mousepox</span>
###xml 693 698 <span type="species:ncbi:10090">mouse</span>
Poxviruses remain a threat to the human population despite the eradication decades ago of naturally circulating variola virus, the causative agent of smallpox. Smallpox, with its up to 30% mortality rate, could devastate the large unvaccinated population if released accidentally or by bioterrorists [1]. Closely related monkeypox virus has also emerged as a human pathogen [2]. To understand the virulence of smallpox, investigators have turned to related poxviruses like ectromelia virus (ECTV), the causative agent of mousepox. Variola virus and ECTV have a narrow host-range and cause significant morbidity and mortality [3],[4]. The numerous available mousepox-susceptible and -resistant mouse strains allow the components of the protective immune response to poxviruses to be dissected in the natural host.
###end p 6
###begin p 7
###xml 244 247 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Buller1">[4]</xref>
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 531 534 531 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chaudhri1">[5]</xref>
###xml 589 590 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 599 602 599 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah1">[6]</xref>
###xml 603 606 603 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang1">[7]</xref>
###xml 616 619 616 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang1">[7]</xref>
###xml 620 623 620 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chaudhri2">[8]</xref>
###xml 637 640 637 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah1">[6]</xref>
###xml 668 671 668 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang2">[9]</xref>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Parker2">[10]</xref>
###xml 701 705 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah2">[11]</xref>
###xml 706 710 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Panchanathan1">[13]</xref>
###xml 736 740 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Panchanathan1">[13]</xref>
###xml 751 755 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mullbacher1">[14]</xref>
###xml 756 760 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Wallich1">[15]</xref>
###xml 782 786 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mullbacher2">[16]</xref>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 133 137 <span type="species:ncbi:10090">Mice</span>
###xml 156 160 <span type="species:ncbi:12643">ECTV</span>
###xml 269 273 <span type="species:ncbi:12643">ECTV</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
Disease severity varies among inbred mouse strains, and comparisons of these strains have elucidated factors essential for survival. Mice naturally acquire ECTV via cutaneous abrasions, which is mimicked experimentally with footpad inoculation [4]. Through this route, ECTV infection is 100% lethal in susceptible strains (BALB/c, DBA/2, and A/J) but asymptomatic in the resistant C57BL/6 strain. The C57BL/6 strain has a stronger TH1 type cytokine response and a more robust cytotoxic lymphocyte response than susceptible strains [5]. Lethal infection occurs in C57BL/6 mice that lack CD8+ T cells [6],[7], B cells [7],[8], macrophages [6], natural killer (NK) cells [9],[10], interferon (IFN)-gamma [11]-[13], IFN alpha/beta receptor [13], perforin [14],[15], and granzyme A or B [16]. Survival, therefore, requires both the adaptive and innate immune response.
###end p 7
###begin p 8
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Roozendaal1">[17]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Gasque1">[19]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Hohler1">[20]</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Seppanen1">[24]</xref>
###xml 220 225 <span type="species:ncbi:9606">human</span>
The innate immune system defends the host during the early phase of an infection and shapes the adaptive response [17]-[19]. The complement system is an essential component of the innate immune system, and evidence from human disease and animal models implicates complement as a critical part of host defense against several virus families [20]-[24].
###end p 8
###begin p 9
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Gasque1">[19]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Blue1">[25]</xref>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Lambris1">[27]</xref>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Endo1">[28]</xref>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Thurman1">[29]</xref>
###xml 957 960 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
The complement system consists of cell-surface and serum proteins that interact to destroy invading microorganisms and infected host cells [19], [25]-[27]. Three distinct pathways activate this cascade: classical, lectin, and alternative (pathway diagram in the results section). Antibody binding to antigen triggers the classical pathway. Mannan-binding lectin (MBL) and related proteins recognize repetitive carbohydrate motifs on pathogens and infected cells to initiate the lectin pathway [28]. Spontaneously activated C3 initiates the alternative pathway, especially if deposited on surfaces deficient in regulatory proteins [29]. The alternative pathway also serves as a positive feedback loop by forming additional C3 convertases from the C3b produced by any pathway. All three pathways converge at the step of C3 cleavage to C3a and C3b, and they share a common terminal pathway that generates the C5a anaphylatoxin and the membrane attack complex (MAC).
###end p 9
###begin p 10
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Blue1">[25]</xref>
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Lambris1">[27]</xref>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Kohl1">[30]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Morgan1">[18]</xref>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Cummings1">[31]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Isaacs1">[33]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Favoreel1">[26]</xref>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Lambris1">[27]</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Lee1">[34]</xref>
###xml 169 172 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Complement system activation can exert multiple antiviral effects [25],[27]. Opsonization of the virion may block attachment or promote destruction by phagocytosis. The MAC disrupts the membrane integrity of the virion or infected cells. The anaphylatoxin cleavage products, C3a and C5a, attract and activate proinflammatory and immune effector cells [30]. Finally, complement activation induces and instructs the adaptive response and augments the neutralizing activity of antibody [18], [31]-[33]. To evade these antiviral activities, viruses use multiple strategies to hinder complement activation [26],[27],[34].
###end p 10
###begin p 11
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Johnston1">[35]</xref>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Turner1">[36]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Alcami1">[39]</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Isaacs1">[33]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Sfyroera1">[40]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Liszewski2">[45]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Liszewski2">[45]</xref>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chen1">[46]</xref>
###xml 833 837 833 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Isaacs1">[33]</xref>
###xml 838 842 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Miller1">[47]</xref>
###xml 257 270 <span type="species:ncbi:10255">Variola virus</span>
###xml 272 287 <span type="species:ncbi:10244">monkeypox virus</span>
###xml 293 297 <span type="species:ncbi:12643">ECTV</span>
###xml 567 582 <span type="species:ncbi:10244">monkeypox virus</span>
###xml 775 789 <span type="species:ncbi:10245">vaccinia virus</span>
In their large double-stranded DNA genomes, poxviruses encode factors that modify the immune response [35]. Study of immunomodulatory molecules has provided insights into viral pathogenesis and revealed novel facets of the host's immune response [36]-[39]. Variola virus, monkeypox virus, and ECTV each produce an orthologous complement regulatory protein that has structural and functional homology to host proteins [33], [40]-[45]. Loss of this complement regulatory protein may account for the reduced virulence seen in the West African vs. Congo basin strains of monkeypox virus [45],[46]. The limits of the monkeypox animal models, however, have made this a difficult hypothesis to test. Loss of the complement regulatory protein affects local lesion size of cowpox and vaccinia virus, but these are non-lethal infection models [33],[47]. Additionally, an incomplete understanding of the role of complement during poxviral infections has complicated the investigation into how these proteins enhance virulence.
###end p 11
###begin p 12
###xml 193 196 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Miller2">[48]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Brownstein1">[49]</xref>
###xml 175 187 <span type="species:ncbi:10243">cowpox virus</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:12643">ECTV</span>
Complement influences poxviral infections, but an essential role for survival has not been demonstrated. One study described increased inflammation at the inoculation site of cowpox virus in C5-/- mice; however, no mortality occurred in these mice [48]. Additionally, an allele for genetic resistance to ECTV mapped to the chromosomal region containing C5 [49].
###end p 12
###begin p 13
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-McFadden1">[3]</xref>
###xml 344 348 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-PaulMorgan1">[50]</xref>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 37 45 <span type="species:ncbi:12643">mousepox</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:12643">ECTV</span>
###xml 665 669 <span type="species:ncbi:12643">ECTV</span>
Using complement-deficient mice, the mousepox model offers an opportunity to characterize the role of this system during infection in the natural host. Use of a model where the host and pathogen have co-evolved is particularly important given the species specificity of many poxviruses and of complement proteins, regulators, and receptors [3],[50]. In this study, we focused on the role of C3, the complement cascade's central component. Resistant C57BL/6 mice that genetically lack C3 inadequately control ECTV infection and have increased morbidity, viral burdens, and mortality. Our in vitro and in vivo evidence suggests that the complement system neutralizes ECTV early in infection and contributes to survival.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 39 43 <span type="species:ncbi:12643">ECTV</span>
C3 Deficiency Increased Mortality from ECTV Inoculated by Multiple Routes
###end title 15
###begin p 16
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Tscharke1">[51]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Schell1">[52]</xref>
###xml 496 499 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 240 244 <span type="species:ncbi:12643">ECTV</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
The route of infection influences the interaction between poxviruses and the host [51]. Half of the 16 mutant vaccinia viruses assessed using two routes of inoculation, ear pinna or intranasal, had a detectible phenotype by only one route. ECTV infections of C57Bl mice by the intranasal, intraperitoneal, or intravenous routes result in severe disease and mortality, while the footpad and intradermal routes cause minimal disease [52]. To examine the role of complement in vivo, wild-type and C3-/- mice were infected by three routes: footpad, ear pinna, and intranasal.
###end p 16
###begin p 17
###xml 154 163 154 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1A</xref>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:12643">ECTV</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
Approximately 95% (54 of 57) of the wild-type mice survived when inoculated with 40,000 pfu of ECTV, the highest dose employed in the footpad infections (Figure 1A). In contrast, C3-/- mice had about 90% mortality at that dose. They also had significantly increased mortality (P<0.0001) at lower doses, even when inoculated with only 4 pfu. The median time to death increased as the dose decreased from 7 days at 40,000 pfu to 9, 10, or 13 days at the lower doses of 4,000, 400, or 4 pfu, respectively.
###end p 17
###begin title 18
###xml 59 63 <span type="species:ncbi:10090">mice</span>
C3 deficiency increased mortality and morbidity in C57BL/6 mice.
###end title 18
###begin p 19
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 916 919 914 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 986 987 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1011 1014 1009 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1077 1080 1075 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1288 1289 1274 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1418 1419 1404 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">Mice</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
###xml 967 971 <span type="species:ncbi:10090">mice</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
###xml 1163 1167 <span type="species:ncbi:10090">Mice</span>
###xml 1210 1214 <span type="species:ncbi:12643">ECTV</span>
###xml 1307 1311 <span type="species:ncbi:10090">Mice</span>
###xml 1332 1336 <span type="species:ncbi:12643">ECTV</span>
(A,C,E) Greater mortality was observed in C3-/- compared to wild-type (WT) C57BL/6 mice by multiple routes of inoculation. The number of animals in each group is right of the line, and the statistics compare the survival of C3-/- and wild-type mice. (B,D,F) C3-/- mice have increased morbidity following infection by the indicated route as monitored by weight loss. Weight loss for individual animals was normalized to their starting weight, and mean+/-SEM is shown. The graph segregates the mice that survived the infection (filled symbols) from those that succumbed (open symbols). The number of animals in each group is presented at the end of the line. (A,B) Mice were inoculated in the footpad with the dose listed to the right of the survival curve or in the legend. The survival curves were generated from two to three separate experiments (except for a single experiment at 4,000 pfu). The survival of the C3-/- mice significantly differed from the wild-type mice at all doses (P<0.0001). (B) The one C3-/- mouse that survived at 40,000 pfu is not shown for clarity. C3-/- mice alive at day 49 continued to gain weight until day 119 post-infection. (C,D) Mice were inoculated with approximately700 pfu ECTV via the ear pinna. The data are combined from four separate experiments (P = 0.0002). (E,F) Mice received 100 pfu of ECTV intranasally. The curves are generated from at least seven separate experiments (P<0.0001).
###end p 19
###begin p 20
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 352 361 352 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1B</xref>
###xml 384 387 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 542 551 530 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1A</xref>
###xml 622 625 610 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 632 633 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
The C3-/- mice also showed increased morbidity over the course of the infection. Unlike the wild-type mice on day 7 post-infection with 40,000 pfu, the C3-/- mice displayed clinical signs of infection, including fur ruffling and hunchbacked posture. Consistent with these observations, C3-/- mice lost more weight at 400 and 40,000 pfu than wild-type (Figure 1B). The few surviving C3-/- mice at the 400 pfu dose required approximately3 additional weeks compared to the wild-type mice to return to their initial weight. All surviving mice in Figure 1A were held for at least 40 days to monitor recovery, and a subset of C3-/- mice (n = 4 at 400 pfu) were held to day 119 post-infection. The mice that survived the acute illness recovered weight steadily and showed no signs of relapse.
###end p 20
###begin p 21
###xml 122 125 122 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Parker1">[2]</xref>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 192 201 192 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1C</xref>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 413 429 413 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1B and 1D</xref>
###xml 562 565 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
The ear pinna studies used a dose of 700 pfu to mimic the low inoculum thought to transmit the natural poxvirus infection [2]. The infection caused 72% mortality in the C3-/- mice (28 of 39) (Figure 1C), compared to 25% in the wild-type mice (6 of 24, P = 0.0002). The surviving C3-/- mice lost less weight and recovered to the initial weight earlier if inoculated by the ear pinna compared to the footpad route (Figure 1B and 1D). In contrast to the increased morbidity and mortality observed, C3 deficiency caused no gross differences in the primary lesion; C3-/- and wild-type mice had similar levels of footpad swelling or necrosis at the ear pinna inoculation site (data not shown).
###end p 21
###begin p 22
###xml 218 219 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 228 237 228 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1E</xref>
###xml 285 288 285 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 387 396 387 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1F</xref>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
To examine the role of C3 in intranasal infection, the dose was lowered to 100 pfu due to the increased susceptibility of the wild-type mice with this route. C3 deficiency increased the mortality rate from 40% to 80% (P<0.0001, Figure 1E). Similar to the other routes, the surviving C3-/- mice had more severe disease than wild-type, as they lost more weight and took longer to recover (Figure 1F).
###end p 22
###begin title 23
###xml 51 55 <span type="species:ncbi:12643">ECTV</span>
C3 Deficiency Resulted in Earlier Dissemination of ECTV to the Target Organs, Higher Peak Viral Titers, and Delayed Viral Clearance
###end title 23
###begin p 24
###xml 137 140 137 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Buller1">[4]</xref>
###xml 0 4 <span type="species:ncbi:12643">ECTV</span>
ECTV replicates at the inoculation site and in the draining lymph node to generate the primary viremia that infects the spleen and liver [4]. Virus released from these target organs causes a secondary viremia, which seeds distal sites like the skin, generating the characteristic pox lesions.
###end p 24
###begin p 25
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 382 385 382 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 460 476 460 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2A and 2B</xref>
###xml 61 65 <span type="species:ncbi:12643">ECTV</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
To begin to dissect how C3 contributed to protection against ECTV, we examined viral burden in two key tissues, the spleen and liver. Wild-type and C3-/- mice were inoculated in the footpad with either 400 or 40,000 pfu, and then spleen and liver tissue were collected on day 7 post-infection. All animals had detectible virus in either the spleen or liver. At the two doses, the C3-/- mice had a 1-2 log higher mean titer than wild-type mice in both tissues (Figure 2A and 2B).
###end p 25
###begin title 26
C3 deficiency promoted earlier dissemination to and increased viral titers in the target organs.
###end title 26
###begin p 27
###xml 2 5 2 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 242 244 242 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 453 456 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 523 526 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 551 552 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1046 1055 1017 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000249.s001">Figure S1</xref>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">Mice</span>
###xml 714 718 <span type="species:ncbi:12643">ECTV</span>
###xml 905 909 <span type="species:ncbi:12643">ECTV</span>
C3-/- and wild-type mice were infected by the footpad or ear pinna route and sacrificed on day 2, 4, 7, or 10 post-infection. The viral titer of the spleen (A,C) or liver (B,D) was determined by direct plaque assay and is expressed as the log10 plaque forming units (PFU)/g tissue. The level of viral DNA in whole blood was measured using quantitative PCR (E). The scatter plots show the viral burden of each wild-type (WT, black, black triangle) and C3-/- (red, *) animal. The error bars indicate SEM. The wild-type and C3-/- mice were compared, and P values <0.05 are reported above the bracket. The dotted line represents the limit of detection for the assay. (A,B) Mice were infected with 400 or 40,000 pfu of ECTV in the footpad and sacrificed on day 7 post-infection. At 400 pfu, all animals had virus detected in either the spleen or liver. (C-E) Animals were infected with approximately700 pfu of ECTV via the ear pinna. Mean viral titers+/-SEM or genome copies+/-SEM from the scatter plots are also plotted against time in a line graph (Figure S1).
###end p 27
###begin p 28
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 273 277 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 285 294 273 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2A</xref>
###xml 386 389 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 470 474 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 544 547 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 626 629 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 667 671 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 677 686 641 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2B</xref>
###xml 859 862 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 916 920 <span type="species:ncbi:10090">mice</span>
In wild-type mice, both doses produced similar maximal tissue titer; however, the higher dose increased the uniformity of the group and, thereby, increased the mean titer. At the 40,000 pfu dose, the splenic viral burden in the C3-/- mice was approximately150-fold higher (P = 0.0002, Figure 2A). Reducing the dose to 400 pfu resulted in approximately25-fold lower viral titer in the C3-/- mice, yet it was still approximately25-fold higher than the wild-type controls (P = 0.03). In contrast, both doses produced similar liver titers in the C3-/- mice. The lower dose revealed an 80-fold increase in the liver titer of the C3-/- mice compared to the wild-type mice (P = 0.01, Figure 2B), while the higher dose showed less of a difference between the strains (15-fold) due to the increased titer in the wild-type mice. Illustrative of the impact of C3, the C3-/- mice at 400 pfu had higher titers than the wild-type mice given 40,000 pfu, a 100-fold more virus.
###end p 28
###begin p 29
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Kapadia1">[21]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Kopf1">[22]</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Ochsenbein1">[53]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mehlhop2">[57]</xref>
###xml 658 661 658 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
These increases in viral titer prompted further exploration of how C3 deficiency impacts viral spread. C3 could control viral replication early at the inoculation site by directly inactivating free virus or by recruiting inflammatory cells through release of anaphylatoxins. The lack of C3 in the blood to neutralize or opsonize the virus could also result in greater viremia, thereby producing the higher titers observed in the target organs on day 7. Alternatively, C3's well-established ability to facilitate induction of antibody and T cell responses could explain the observed difference [21], [22], [53]-[57]. To elucidate when the infections in the C3-/- and wild-type mice diverge, we inoculated via the ear pinna route and examined the viral burden in the blood, spleen, and liver on days 2, 4, 7, and 10 post-infection. The ear pinna route was selected for further analysis because it is a cutaneous route of inoculation that mimics a natural infection of the epithelium where complement may promote containment.
###end p 29
###begin p 30
###xml 191 200 191 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2E</xref>
###xml 291 294 291 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
Using whole blood enables an unbiased detection of all virus, whether free in the plasma or in infected cells. Quantitative PCR was employed to detect viral DNA in blood on days 2, 4, and 7 (Figure 2E). A few day 2 samples contained viral DNA, but most were below the detection limit. The C3-/- mice had 2.0- and 2.5-fold higher levels of viral DNA than wild-type mice had on days 4 and 7 (P = 0.004 and 0.03, respectively).
###end p 30
###begin p 31
###xml 108 111 108 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 187 196 187 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2C</xref>
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 295 304 295 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2D</xref>
###xml 365 366 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 431 440 431 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1D</xref>
###xml 521 537 521 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2C and 2D</xref>
###xml 577 580 577 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1C</xref>
###xml 696 697 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
Despite the low levels of viremia on day 2, infectious virus was present in the spleen of over 70% of the C3-/- mice (13 of 18) compared to 28% of the wild-type mice (5 of 18, P = 0.006, Figure 2C). By day 7 post-infection, the C3-/- mice had 45-fold higher viral titers in the liver (P = 0.01, Figure 2D), and there was also a similar trend in the spleen (6-fold, P = 0.09). The wild-type mice regained weight starting on day 10 (Figure 1D), and by then over 80% had cleared the virus from the spleen or liver (9 of 11, Figure 2C and 2D). In contrast, less than half of the C3-/- mice survived to day 10 (Figure 1C), and of these, over 75% had ongoing infection of the spleen and liver (7 of 9, P = 0.008 and 0.01, respectively).
###end p 31
###begin p 32
###xml 164 167 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
In summary, C3 deficiency resulted in earlier dissemination to spleen and in higher peak titers in the liver. The viral infection also continued to day 10 in the C3-/- when it had been cleared by most wild-type mice.
###end p 32
###begin title 33
C3 Deficiency Increased Hepatic Inflammation and Necrosis
###end title 33
###begin p 34
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Jacoby1">[58]</xref>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fenner1">[59]</xref>
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
###xml 30 34 <span type="species:ncbi:12643">ECTV</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
In susceptible mouse strains, ECTV causes extensive hepatic and splenic necrosis [58],[59]. We compared C3-/- and wild-type mice for histopathological changes in the liver on days 4, 7, and 10 post-infection.
###end p 34
###begin p 35
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 213 221 213 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3</xref>
###xml 306 322 306 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3A and 3B</xref>
###xml 342 345 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 352 368 352 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3C and 3D</xref>
###xml 529 545 529 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3B and 3C</xref>
###xml 592 601 592 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3D</xref>
###xml 849 857 849 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4</xref>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
On day 4, the liver histopathology appeared normal in 4 of 5 wild-type and 3 of 4 C3-/- mice (data not shown). By day 7, all animals had a diffuse lymphocytic infiltrate in addition to discrete inflammatory foci (Figure 3). These lesions varied in size and were smaller and less frequent in the wild-type (Figure 3A and 3B) compared to the C3-/- mice (Figure 3C and 3D). They often occurred near the portal triad, and some contained areas of coagulative necrosis. An inflammatory infiltrate encircled the discrete necrotic foci (Figure 3B and 3C) and bordered the areas of bridging necrosis (Figure 3D). In contrast to the liver, no major differences were observed in the spleen at this time (data not shown). Using blinded samples, we counted the necrotic and non-necrotic foci and evaluated the location and severity of the necrosis in the liver (Figure 4).
###end p 35
###begin title 36
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Extensive liver necrosis occurred in C3-deficient mice.
###end title 36
###begin p 37
###xml 758 761 746 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 827 830 815 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Liver samples were taken from mice 7 days after infection with approximately700 pfu via ear pinna, fixed, sectioned, and stained with hematoxylin and eosin. Representative images show the range of differences between the strains. White lines border coalesced areas of necrosis. Arrowheads point to non-necrotic inflammatory foci. T, portal triad; V, central vein. (A) Wild-type-blood flows through the liver from zone 1 to 3, as indicated by the arrow. Zone 1 encircles the portal triad, zone 3 encircles the central vein, and zone 2 occurs between zones 1 and 3. There are small inflammatory foci adjacent to two portal triads. (B) Wild-type-there are inflammatory foci adjacent to portal triads, and one focus has a small area of confluent necrosis. (C) C3-/--larger inflammatory foci with areas of confluent necrosis. (D) C3-/--an inflammatory infiltrate borders the extensive necrosis that bridges across all three zones (T-->V).
###end p 37
###begin title 38
###xml 13 17 <span type="species:ncbi:10090">mice</span>
C3-deficient mice had a greater number of inflammatory foci with more extensive necrosis.
###end title 38
###begin p 39
###xml 50 53 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 87 88 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 817 826 792 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3A</xref>
###xml 1008 1009 983 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1081 1084 1056 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
###xml 1099 1103 <span type="species:ncbi:10090">mice</span>
(A-F) Wild-type (WT, black, black triangle) and C3-/- (red, *) mice were compared, and P values are above the bracket. Error bars are SEM. (A) The number of inflammatory foci/visual field was counted. Each point represents the mean from approximately7 fields for an individual mouse. The graph plots the mean number of foci for each animal. (B) The number of inflammatory foci containing necrosis was counted and displayed as described in (A). (C) The percentage of foci that contained areas of necrosis. (D) The severity of the necrosis was quantitated using a 0-4 scale: 0, none; 1, piecemeal necrosis; 2, confluent areas of necrosis; 3, confluent areas of necrosis that extend beyond a single zone; and 4, bridging necrosis. (E) The zones of the liver (1, 2, and 3) where necrosis occurred. Zones are described in Figure 3A. (F) The serum levels of the liver enzymes in uninfected mice were <100 for AST and <50 for ALT. (G) AST (blue) and ALT (black) levels positively correlate with liver viral titer (r2 = 0.54 and 0.69, respectively). The log of these parameters for both C3-/- and wild-type mice was used for linear regression.
###end p 39
###begin p 40
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 217 226 217 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4A</xref>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 311 320 311 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4B</xref>
###xml 405 408 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 464 473 464 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4C</xref>
###xml 482 485 482 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 547 556 547 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4D</xref>
###xml 682 698 682 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3A and 3B</xref>
###xml 734 737 734 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 863 879 863 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g003">Figure 3C and 3D</xref>
###xml 1030 1039 1030 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4E</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
There were prominent differences between the C3-/- and wild-type mice relative to the number inflammatory foci and in the degree of necrosis. The C3-/- mice had twice as many total foci (8 vs. 18 per field, P = 0.02, Figure 4A) and 5-fold more foci containing regions of necrosis (3 vs. 15 per field, P = 0.03, Figure 4B). The majority of inflammatory foci contained necrotic areas in two-thirds of the C3-/- mice compared to only one-fifth of the wild-type mice (Figure 4C). The C3-/- mice had larger foci with more extensive necrosis (P = 0.02, Figure 4D). Most wild-type mice had small foci with either no necrosis or only piecemeal necrosis (0 and 1 on necrosis severity scale, Figure 3A and 3B, respectively). In contrast, the C3-/- mice had confluent areas of necrosis that coalesced into bands of bridging necrosis (2 and 4 on the necrosis severity scale, Figure 3C and 3D, respectively). Given that necrosis most frequently occurred in zone 1 of the liver, it likely originated there and then extended into zones 2 and 3 (Figure 4E).
###end p 40
###begin p 41
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 218 227 218 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4F</xref>
###xml 298 307 298 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4G</xref>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
The increased hepatic necrosis in the C3-/- mice resulted in higher levels of liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), in the serum on day 7 (P = 0.008, 0.0503, respectively, Figure 4F). The AST and ALT levels positively correlated with the viral burden (Figure 4G).
###end p 41
###begin p 42
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 43 52 43 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">Figure 1C</xref>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 276 279 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 337 346 325 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g002">Figure 2D</xref>
###xml 11 15 <span type="species:ncbi:10090">mice</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:12643">ECTV</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
Most C3-/- mice died between day 7 and 10 (Figure 1C). Two C3-/- mice that were sacrificed on day 10 had approximately5-7 inflammatory foci per field, while the 5 wild-type mice had only occasional foci (data not shown). At this time point, infectious ECTV persisted in the C3-/- mice; whereas, wild-type mice had cleared the infection (Figure 2D).
###end p 42
###begin title 43
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 29 33 <span type="species:ncbi:12643">ECTV</span>
Mouse Complement Neutralized ECTV Intracellular Mature Virions
###end title 43
###begin p 44
###xml 42 46 <span type="species:ncbi:12643">ECTV</span>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 97 101 <span type="species:ncbi:12643">ECTV</span>
###xml 150 154 <span type="species:ncbi:12643">ECTV</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
To explore the interaction between C3 and ECTV in vivo, we examined how mouse complement affects ECTV virions in vitro. Purified intracellular mature ECTV was incubated with either EDTA-treated plasma or sera from naive C57BL/6 mice. Infectious virus was detected as plaques on a BS-C-1 monolayer. EDTA-treated plasma was reconstituted with a buffer containing calcium and magnesium to allow for complement activation.
###end p 44
###begin p 45
###xml 75 84 75 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5A</xref>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 260 269 260 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5B</xref>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 254 258 <span type="species:ncbi:12643">ECTV</span>
###xml 349 353 <span type="species:ncbi:12643">ECTV</span>
Reconstituted wild-type plasma neutralized approximately 90% of the virus (Figure 5A, P<0.001). Heat inactivation or buffer lacking calcium and magnesium abolished neutralization. Wild-type sera concentrations of 10, 25, or 50% neutralized 70-80% of the ECTV (Figure 5B, P<0.0001). These observations implicate the complement system in neutralizing ECTV.
###end p 45
###begin title 46
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 41 45 <span type="species:ncbi:12643">ECTV</span>
The murine complement system neutralized ECTV virions.
###end title 46
###begin p 47
###xml 771 772 763 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 967 968 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1272 1273 1264 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1781 1782 1772 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1793 1794 1784 1785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1806 1807 1797 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1892 1895 1883 1886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1901 1904 1892 1895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1958 1961 1949 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1968 1971 1959 1962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2289 2292 2279 2282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2294 2295 2284 2285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2348 2349 2338 2339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2936 2939 2924 2927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2946 2949 2934 2937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2992 2995 2980 2983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 6 10 <span type="species:ncbi:12643">ECTV</span>
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
###xml 465 470 <span type="species:ncbi:10090">Mouse</span>
###xml 490 494 <span type="species:ncbi:12643">ECTV</span>
###xml 496 500 <span type="species:ncbi:12643">ECTV</span>
###xml 538 543 <span type="species:ncbi:10090">mouse</span>
###xml 993 998 <span type="species:ncbi:10090">Mouse</span>
###xml 1017 1021 <span type="species:ncbi:12643">ECTV</span>
###xml 1023 1027 <span type="species:ncbi:12643">ECTV</span>
###xml 1108 1113 <span type="species:ncbi:10090">mouse</span>
###xml 1261 1265 <span type="species:ncbi:12643">ECTV</span>
###xml 1393 1397 <span type="species:ncbi:10090">mice</span>
###xml 2858 2861 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 4067 4070 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
(A-G) ECTV was incubated with a mouse complement source at 37degreesC for 1 hour and then added to BSC-1 monolayers. The absolute number of plaques was normalized to the appropriate controls (white bars) to give the relative number of plaques. Graphs display mean+/-SEM from multiple experiments. All data were analyzed using 1-way ANOVA followed by the Tukey multiple comparison test except (B), which used a 2-way ANOVA to analyze concentration and activity. (A) Mouse plasma neutralizes ECTV. ECTV was combined with 10% wild-type (WT) mouse EDTA-treated plasma or heat-inactivated (HI) plasma in gelatin veronal buffer (GVB) in the presence or absence of calcium and magnesium (Ca/Mg). The active plasma (in the presence of Ca/Mg) differed from all other groups (***, P<0.001). These data were combined from nine independent experiments using EDTA plasma collected on three separate days. The total number of replicates for each column from left to right follows: n = 25, 29, 17, 7, 3. (B) Mouse serum neutralizes ECTV. ECTV was incubated with increasing concentrations of HI (white) or active (black) WT mouse sera. Data represent three to four independent experiments performed in duplicate with four different collections of sera. Active sera neutralized ECTV (***, P<0.0001), at multiple concentrations. (C-G) The relative roles of the complement pathways were analyzed using sera from mice genetically deficient in complement components (C3, C4, C1q, MBL A and MBL C, FB, FD, or C5) or antibody (muMT). A final concentration of 50% sera was used in all cases. Data were combined from at least two experiments performed in duplicate with independent collections of sera. Unless noted specifically below, the significant differences are displayed on the graph as follows: *, P<0.05; **, P<0.01; ***, P<0.001. Any significant differences among grouped bars are noted on the graph. (C) C3-/- or C4-/- sera have reduced neutralizing capacity. Combining C3-/- and C4-/- sera restored neutralizing activity to WT levels. WT-HI differed from the other conditions (***). Data were from at least three experiments performed in duplicate. (D) Deficiencies in the classical pathway (C4, C1q) and antibody (muMT), but not the lectin pathway (MBL), reduce neutralization. WT-HI differed from C1q-/- (P<0.01) and differed from the rest of the conditions (P<0.001). Data were from at least two experiments performed in duplicate. (E) Neutralizing activity requires the alternative pathway components: FB, FD, and C3. WT-HI differed from the other conditions (***). Data were from at least two experiments performed in duplicate. (F) Addition of either 10% or 25% WT-HI sera restores the neutralizing activity of antibody-deficient muMT sera to WT capacity. Heat inactivation of muMT sera reduces neutralization. Data were from two experiments done in duplicate. (G) MAC (C5b-9) formation enhances neutralization but is not required. Both the C5+/+ and C5-/- sera had greater neutralization than HI-C5+/+. The buffer only control (GVBdegrees) is equivalent to WT-HI. Data combined from three experiments performed in triplicate. (H) The classical, lectin, and alternative pathways each initiate the complement cascade by forming a C3 convertase that cleaves C3 to C3b. Antibody triggers the classical pathway through C1q. The carbohydrate motifs on pathogens activate the lectin pathway through MBL. The classical and lectin pathways form the C4 containing convertase, C4b2a. C3 deposited from these two pathways or from spontaneous activation of C3 initiates the alternative pathway. Upon binding, the activated C3 molecule FB is cleaved to Bb by FD, which forms the alternative pathway convertase, C3bBb. The alternative pathway amplifies C3b deposition by any pathway. C3 activation leads to important antiviral effector functions. Release of the anaphylatoxins C3a and C5a recruits inflammatory cells. C3b and C4b opsonize viral particles or infected cells, leading to neutralization or destruction by phagocytosis. C3b also leads to activation of C5 and formation of the MAC which disrupts virions or infected cells.
###end p 47
###begin p 48
###xml 150 162 150 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g004">Figure 4C&#8211;4G</xref>
###xml 259 268 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5C</xref>
###xml 289 292 277 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 299 302 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 44 48 <span type="species:ncbi:12643">ECTV</span>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
To further define if complement neutralized ECTV, sera from mice genetically deficient in a complement component or antibody were used in this assay (Figure 4C-4G). The neutralizing activity was reduced by approximately50% with deficiency of either C3 or C4 (Figure 5C). However, mixing C3-/- and C4-/- sera produced results equivalent to wild-type sera.
###end p 48
###begin p 49
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 221 224 221 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 284 293 283 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5D</xref>
###xml 307 310 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 365 368 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 33 37 <span type="species:ncbi:12643">ECTV</span>
###xml 343 347 <span type="species:ncbi:12643">ECTV</span>
###xml 557 561 <span type="species:ncbi:12643">ECTV</span>
This requirement for C4 for full ECTV neutralization was further dissected. The C1q subunit of C1 interacts with antibody to trigger the classical pathway. MBL, a C1q analog, initiates the lectin pathway. MBL A-/- x MBL C-/-, C1q-/-, and antibody-deficient (muMT) sera were compared (Figure 5D). muMT or C1q-/- sera only partially neutralized ECTV, comparable to C4-/- sera. Conversely, wild-type levels of neutralization occurred independent of MBL A and C. These data suggest that natural antibody activated the classical complement pathway to neutralize ECTV.
###end p 49
###begin p 50
###xml 274 290 274 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5A and 5G</xref>
###xml 416 425 415 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5F</xref>
###xml 268 272 <span type="species:ncbi:12643">ECTV</span>
###xml 530 534 <span type="species:ncbi:12643">ECTV</span>
Further analysis revealed three key points relative to natural antibody. First, heat-inactivated wild-type sera behaves like buffer alone, which indicates that natural antibody alone lacks neutralizing activity; instead, complement activity was required to neutralize ECTV (Figure 5A and 5G). Second, heat-inactivated wild-type sera, as a source of natural antibody, restored the neutralizing activity of muMT sera (Figure 5F). Consistent with this finding, muMT or heat-inactivated wild-type serum did not effectively neutralize ECTV independently, but they did so in combination. Third, the modest but significantly greater neutralization in the normal compared to heat-inactivated muMT sera suggests that antibody-independent (alternate pathway) complement activation also occurred.
###end p 50
###begin p 51
###xml 257 260 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 267 270 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 294 297 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 303 306 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 355 364 354 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5E</xref>
###xml 329 333 <span type="species:ncbi:12643">ECTV</span>
C3b deposited by any pathway interacts with factor B (FB) and factor D (FD) to generate the alternative pathway C3 convertase, which amplifies C3b production. Alternative pathway activation itself likely explains the neutralization observed in the muMT, C1q-/-, or C4-/- sera. Interestingly, FB-/- or FD-/- sera neutralized less ECTV than wild-type sera (Figure 5E), which indicates that the alternative pathway enhanced complement-mediated neutralization initiated by the classical pathway.
###end p 51
###begin p 52
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 379 388 379 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g005">Figure 5G</xref>
###xml 393 396 393 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 477 480 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 21 25 <span type="species:ncbi:12643">ECTV</span>
###xml 172 175 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 226 229 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 356 359 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 603 606 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
C3b could neutralize ECTV by directly preventing attachment to or entry into the cell or by disrupting the virion's membrane through formation of the C5 convertase and the MAC. C5 initiates the terminal pathway that forms the MAC, and no lytic activity occurs in the absence of C5. C5-/- sera from C57BL/10 mice were used to define the contribution of the MAC to neutralization (Figure 5G). C5-/- sera neutralized a significant portion of virus (P<0.001), however, less than C5+/+ sera (P<0.05). These findings suggest that opsonization by C4b and C3b mediated most of the neutralization; although, the MAC also contributed.
###end p 52
###begin p 53
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
###xml 84 88 <span type="species:ncbi:12643">ECTV</span>
###xml 134 138 <span type="species:ncbi:12643">ECTV</span>
###xml 363 367 <span type="species:ncbi:12643">ECTV</span>
###xml 464 467 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
To conclude, these findings demonstrate that naive wild-type mouse sera neutralized ECTV. We propose that natural antibodies bound to ECTV and triggered the classical pathway. This led to C4b deposition, formation of the C3 convertase, and C3b deposition on the virus. The alternative pathway amplified the C3b placed on the virion by the classical pathway. Most ECTV neutralization occurred through opsonization by C4b and C3b, with a minor contribution from the MAC.
###end p 53
###begin title 54
###xml 10 14 <span type="species:ncbi:12643">ECTV</span>
Surviving ECTV Infection Required Multiple Complement Pathways
###end title 54
###begin p 55
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 164 167 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 218 221 218 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 356 365 356 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figure 6A</xref>
###xml 374 377 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 384 387 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 435 445 435 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figures 6C</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">1D</xref>
###xml 59 63 <span type="species:ncbi:12643">ECTV</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
Both the classical and alternative pathways contributed to ECTV neutralization in vitro. To examine the importance of each pathway in vivo, we compared C4-/- and FB-/- mice to C3-/- and wild-type mice. We challenged C4-/- mice via the ear pinna route and monitored survival and weight loss. Over 90% of the C4-/- mice succumbed to the infection (P<0.0001, Figure 6A). The C4-/- and C3-/- mice had comparable mortality and weight loss (Figures 6C and 1D).
###end p 55
###begin title 56
Deficiency of classical or alternative pathway components reduced survival.
###end title 56
###begin p 57
###xml 8 11 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 446 449 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 453 456 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 464 467 452 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 496 497 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 630 631 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 685 688 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 928 929 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 952 953 938 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1007 1008 993 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:12643">ECTV</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">Mice</span>
###xml 689 694 <span type="species:ncbi:10090">mouse</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:12643">ECTV</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:12643">ECTV</span>
###xml 1157 1161 <span type="species:ncbi:10090">mice</span>
###xml 1207 1211 <span type="species:ncbi:10090">mice</span>
###xml 1247 1251 <span type="species:ncbi:12643">ECTV</span>
###xml 1322 1326 <span type="species:ncbi:10090">mice</span>
###xml 1567 1571 <span type="species:ncbi:10090">mice</span>
(A,C) C4-/- mice have greater mortality than wild-type (WT, P<0.0001). C4-/- mice were compared to C3-/- and wild-type mice following inoculation with approximately700 pfu ECTV via the ear pinna. The weights of the surviving animals (filled symbols) are separated from those that succumbed (open symbols). The number of animals in each group is at the right of the line. The data combine four separate experiments. (B,D) Increased mortality in C4-/-, FB-/-, and C3-/- mice compared to wild-type (P<0.0001). Mice received 100 pfu intranasally. Data are displayed as described above. Curves are generated from multiple experiments (n for WT = 8, C4 = 6, FB = 4, C3 = 7). The surviving FB-/- mouse was omitted from (D) for clarity. (E) muMT mice are susceptible to ECTV via the footpad route. muMT mice were challenged with ECTV, and a dose-dependent increase in mortality was observed. The 50,000 pfu dose differs from 5,000 pfu (P = 0.006) and 500 pfu (P<0.0001), and the lower doses differ from each other (P = 0.045). Survival curves were constructed from four separate experiments, and the number of animals is to right of the legend. (F,G) Treating muMT mice with natural antibody delays mortality. muMT mice were challenged with high doses of ECTV (100,000 pfu) via the footpad route in two separate experiments. Some mice received wild-type sera as a source of natural antibody, while others received muMT sera (1 ml on day minus-1 followed by 0.5 ml on days 0, 2, 4, 6, 8, 10). The untreated curve in (G) includes the historical control data from the untreated mice at 50,000 pfu in (E). The number of animals in each group is next to the legend.
###end p 57
###begin p 58
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 260 269 260 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figure 6B</xref>
###xml 341 351 341 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figures 6D</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g001">1F</xref>
###xml 11 15 <span type="species:ncbi:12643">ECTV</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:12643">ECTV</span>
Intranasal ECTV infection also produced similar results in the C3-/-, C4-/-, or FB-/- mice. Each complement-deficient strain had a higher mortality rate compared the wild-type mice (P<0.0001), and there were no significant differences among the three strains (Figure 6B). The complement-deficient strains also lost weight at a similar rate (Figures 6D and 1F). Thus, control of ECTV in vivo required both the alternative and classical pathways, analogous to the in vitro results.
###end p 58
###begin title 59
###xml 43 47 <span type="species:ncbi:10090">Mice</span>
Natural Antibody Delayed Mortality in muMT Mice
###end title 59
###begin p 60
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Roozendaal1">[17]</xref>
###xml 363 372 362 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figure 6E</xref>
###xml 486 489 485 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chaudhri1">[5]</xref>
###xml 159 163 <span type="species:ncbi:12643">ECTV</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:12643">ECTV</span>
Complement poses a barrier to the systemic spread of pathogens, particularly through the bloodstream [17]. The major role of complement could be to neutralize ECTV recognized by natural antibody. Our prior experiments established that B cell-deficient muMT mice challenged with a high dose of ECTV by the footpad route all died early in infection (94% by day 8) (Figure 6E). Their early death suggests that B cells contribute to survival prior to the rise of specific antibody on day 7 [5].
###end p 60
###begin p 61
###xml 50 54 50 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Jayasekera1">[60]</xref>
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Ochsenbein2">[61]</xref>
###xml 240 257 239 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ochsenbein et al.</italic>
###xml 257 261 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Ochsenbein2">[61]</xref>
###xml 372 381 369 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figure 6F</xref>
###xml 669 678 665 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000249-g006">Figure 6G</xref>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:12643">ECTV</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:12643">ECTV</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
Based on our in vitro data and the data of others [60],[61], we hypothesized that natural antibody contributes to early protection. Consequently, providing muMT mice with natural antibody should prolong their survival. Based on the work of Ochsenbein et al.[61], muMT mice infected with a high dose of ECTV were treated with naive sera from either muMT or wild-type mice (Figure 6F). Treatment with wild-type sera increased the median day of death from 7 to 9; however, sera lacking natural antibodies (muMT) had no effect. On day 8 post-infection, over half of the mice receiving wild-type sera outlived both other groups and 16 of 17 mice from the prior experiments (Figure 6G). Thus, natural antibody delayed, but did not prevent, lethal ECTV infection in muMT mice.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 62 66 <span type="species:ncbi:12643">ECTV</span>
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
###xml 281 285 <span type="species:ncbi:12643">ECTV</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 454 458 <span type="species:ncbi:12643">ECTV</span>
###xml 690 695 <span type="species:ncbi:10090">mouse</span>
We investigated the impact of complement deficiency using the ECTV mouse model. Deficiency of C3, C4, or FB resulted in acute lethal infection, establishing a requirement for multiple complement pathways in host defense against this pathogen. Specifically, C3 deficiency permitted ECTV to disseminate earlier, reach a higher titer in the target organs, and induce greater liver damage. Consistent with these in vivo results, naive mouse sera neutralized ECTV infectivity in vitro, and sera lacking either classical or alternative pathway components had decreased activity. Several lines of evidence indicate that natural antibody initiated the classical complement cascade in the wild-type mouse. Substantial neutralization occurred in sera without lytic activity, which points to opsonization as the predominant mechanism of neutralization. Based on these results, we propose that natural antibody binds viral antigen to activate the classical pathway, followed by engagement of the alternative pathway's feedback loop to opsonize the virus.
###end p 63
###begin p 64
###xml 4 8 <span type="species:ncbi:12643">ECTV</span>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 148 152 <span type="species:ncbi:12643">ECTV</span>
###xml 232 245 <span type="species:ncbi:10255">variola virus</span>
###xml 249 255 <span type="species:ncbi:9606">humans</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
The ECTV model system provides several advantages for analyzing the role of complement in poxviral pathogenesis. First, the mouse-specific pathogen ECTV has coevolved with and causes severe disease in the natural host, analogous to variola virus in humans. Second, the role of complement and the pathways involved can now be more rigorously dissected in vivo and in vitro with the availability of complement-deficient mice. Additionally, the in vitro experiments employed sera from the same strains used to characterize the effect of complement deficiency in vivo, and the neutralizing capacity in vitro paralleled the in vivo mortality. Third, viral pathogenesis, morbidity, and mortality can be assessed by multiple routes of infection and across a range of viral inoculum to demonstrate a broad requirement for complement.
###end p 64
###begin p 65
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 300 297 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah1">[6]</xref>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang1">[7]</xref>
###xml 315 318 315 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang2">[9]</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Parker2">[10]</xref>
###xml 339 343 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah3">[12]</xref>
###xml 379 380 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 389 392 385 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Karupiah1">[6]</xref>
###xml 423 426 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang1">[7]</xref>
###xml 487 490 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 500 503 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 599 580 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 45 49 <span type="species:ncbi:12643">ECTV</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
Complement-deficient mice succumbed to acute ECTV infection with the majority of deaths occurring between days 6-10. Based on time to death following footpad inoculation, C3 deficiency resembled immunodeficiencies of other important components of the antiviral response, specifically CD8+ T cells [6],[7], NK cells [9],[10], and IFN-gamma [12]. In contrast, mice deficient in CD4+ T cells [6], CD40, or CD40 ligand (CD154) [7] survive the acute phase but do not clear the virus. The CD40-/- and CD154-/- mice ultimately die approximately4 to 8 weeks post-infection. This differs from surviving C3-/- mice, which recovered and did not show signs of ongoing illness for up to 4 months of observation. The early death of the complement-deficient mice highlights the complement system's essential contribution to survival during the first few days of infection.
###end p 65
###begin p 66
###xml 295 298 295 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Buller1">[4]</xref>
###xml 145 149 <span type="species:ncbi:12643">ECTV</span>
To characterize how complement protects the host from lethal infection, we analyzed the impact of C3 deficiency on the kinetics of viral spread. ECTV replication at the inoculation site and in the draining lymph node produces a viremia that seeds the primary target organs, the liver and spleen [4]. Several observations from this study increase our understanding of complement's role in controlling poxviral infection.
###end p 66
###begin p 67
###xml 389 392 389 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 668 671 656 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1081 1084 1069 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1203 1207 1191 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Xu1">[62]</xref>
###xml 70 74 <span type="species:ncbi:12643">ECTV</span>
###xml 216 220 <span type="species:ncbi:12643">ECTV</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:12643">ECTV</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
###xml 1131 1135 <span type="species:ncbi:10090">mice</span>
###xml 1237 1241 <span type="species:ncbi:10090">mice</span>
###xml 1285 1289 <span type="species:ncbi:12643">ECTV</span>
First, as early as day 2, C3 deficiency allowed for greater spread of ECTV from the inoculation site to the spleen. This indicates that complement is a key player in the initial hours of infection, likely to control ECTV at the inoculation site. Second, we detected higher levels of viral DNA in the blood on days 4 and 7. Consistent with our in vitro data, these results establish that C3-/- mice poorly control viral dissemination through the bloodstream. This higher viremia could result from increased replication in tissues and/or decreased clearance of virus from the bloodstream. Third, the liver viral titers on day 7 were approximately50-fold higher in the C3-/- mice. The greater viremia likely produced more extensive infection, but a delayed adaptive immune response may also have contributed to this observation. The viral titer correlated with serum levels of ALT, which suggests that ECTV caused hepatic necrosis either directly through lytic infection or indirectly through the antiviral immune response. An inflammatory infiltrate surrounded the necrosis in the C3-/- mice, which contrasts with susceptible Balb/c mice where necrosis occurs in the absence of a lymphocytic infiltration [62]. In summary, we propose that mice lacking C3 have reduced ability to control ECTV locally and in the bloodstream, leading to higher levels of infection and greater tissue damage in the liver.
###end p 67
###begin p 68
###xml 932 935 931 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 942 945 941 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 276 280 <span type="species:ncbi:12643">ECTV</span>
###xml 327 331 <span type="species:ncbi:12643">ECTV</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 396 400 <span type="species:ncbi:12643">ECTV</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 970 973 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 1266 1270 <span type="species:ncbi:12643">ECTV</span>
###xml 1341 1344 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Complement could delay viral dissemination by opsonizing and thereby neutralizing virions at the inoculation site or in the circulation and by promoting the inflammatory response including the recruitment of phagocytic cells. To assess if complement could directly neutralize ECTV, we examined the interaction between purified ECTV and mouse complement in vitro. Naive plasma or sera neutralized ECTV in a complement-dependent manner, even at a concentration as low as 10%. Sera from mice deficient in specific complement components demonstrated that maximal neutralization required both the classical and alternative pathways. muMT sera, lacking antibody, resembled the sera deficient in the classical pathway components, C1q or C4, and addition of a natural antibody source restored neutralization activity. Opsonization led to neutralization of the majority of virus; however, the modest but significant difference between the C5-/- and C5+/+ sera indicates that the MAC contributed to viral damage. Interestingly, no complement component deficiency tested fully abolished neutralization. The residual activity suggests that the classical and alternative pathways functioned independently, likely because both C4b and C3b opsonized and, consequently, neutralized ECTV. However, the system was most effective when the two pathways and the MAC worked cooperatively.
###end p 68
###begin p 69
###xml 249 253 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Jayasekera1">[60]</xref>
###xml 254 258 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Ochsenbein2">[61]</xref>
###xml 649 652 634 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chaudhri2">[8]</xref>
###xml 665 668 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fang1">[7]</xref>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
The reconstitution of the neutralization activity in the muMT sera with heat-inactivated wild-type sera suggests that natural antibody is important in the neutralization process. Consistent with this observation and prior studies with other viruses [60],[61], natural antibody passively transferred into muMT mice lengthened survival during the acute infection. In our experiments, most muMT mice died early, with 100% mortality by day 9 at the highest inoculum. The mice that survived the acute infection eventually died at approximately2 months post-infection. Our findings differ from prior studies, which described mortality at either 2-4 weeks [8] or 2 months [7] post-infection. More of our mice survived the acute infection at the lower doses. This suggests that the observed discrepancy could be secondary to differences in the viral stock or dose, as both differed among the three groups. The death of the muMT mice, despite natural antibody treatment, indicates that B cells help control the infection by additional mechanisms.
###end p 69
###begin p 70
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Smith1">[63]</xref>
###xml 697 701 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Vanderplasschen1">[64]</xref>
###xml 920 924 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Ochsenbein2">[61]</xref>
###xml 514 528 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 620 625 <span type="species:ncbi:9606">human</span>
###xml 630 636 <span type="species:ncbi:9986">rabbit</span>
###xml 1051 1055 <span type="species:ncbi:12643">ECTV</span>
###xml 1104 1118 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 1123 1127 <span type="species:ncbi:12643">ECTV</span>
Our in vitro experiments provide a model for understanding the fate of the viral inoculum in our in vivo experiments, since they both used the same stock of purified intracellular mature virus (IMV). To understand the spread of infection, a second infectious form must be considered. During viral replication in the host cell, extracellular enveloped virus (EEV) is produced by enveloping the IMV with an additional unique membrane derived from the Golgi complex and late endosomal compartment [63]. In studies of vaccinia virus, the host's complement regulators, present in the outermost membrane, protect the EEV from human and rabbit complement; in contrast, the IMV is sensitive to complement [64]. Our study builds on this observation by determining the contribution of each complement activation pathway to the neutralization of IMV infectivity, and it implicates natural antibody as the primary initiating factor [61]. We also show that natural antibody by itself is ineffective but requires augmentation by the complement system to neutralize ECTV. Additionally, the neutralization observed with vaccinia virus and ECTV points to the IMV form being inherently susceptible to complement-mediated neutralization.
###end p 70
###begin p 71
###xml 163 167 <span type="species:ncbi:12643">ECTV</span>
The relative importance of IMV vs. EEV during infection in vivo is not well established. However, the IMV's sensitivity to complement neutralization suggests that ECTV likely travels through areas featuring efficient complement activation, such as the blood stream, in the EEV form or within infected cells. At extravascular sites, where complement levels are lower than in circulation, infected cells may produce sufficient soluble poxviral complement regulatory protein to protect the IMV.
###end p 71
###begin p 72
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Schell1">[52]</xref>
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:12643">ECTV</span>
###xml 689 693 <span type="species:ncbi:12643">ECTV</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
Most poxvirus disease models initiate infection with the complement-sensitive IMV. If complement activity in the mouse behaves as it does in vitro, then inoculated ectromelia IMV should be recognized by natural antibody and coated with C4b and C3b, resulting in neutralization of viral infectivity at the site of injection and inhibition of spread. This line of reasoning could explain why the mortality increases in the wild-type mice as the invasiveness of the route decreases [52]. Percutaneous inoculation would likely result in neutralization, while application to the mucosal membranes might enable ECTV to enter host cells before being neutralized by complement. Once internalized, ECTV produces its regulatory protein and EEV to evade complement and propagate the infection. Additionally, based on the in vitro data, complement deficiency would greatly limit this initial neutralization, which likely contributes to the early spread and greater mortality observed in the complement-deficient mice.
###end p 72
###begin p 73
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Helmy1">[65]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mims1">[66]</xref>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mims1">[66]</xref>
###xml 426 430 <span type="species:ncbi:12643">ECTV</span>
A sub-neutralizing concentration of complement opsonins could target the virion for immune adherence and phagocytosis in vivo, particularly in blood with its high complement levels. Furthermore, the liver sinusoids are lined with Kupffer cells bearing CRIg (Complement Receptor of the Ig superfamily), which mediates phagocytosis of C3-opsonized pathogens [65]. Indeed, the liver clears over 95% of intravenously administered ECTV from the circulation within 5 min of injection [66]. In the following hour, most of the viral antigen in the liver becomes undetectable by immunofluorescence, and viral infectivity decreases by over 90%. This rapid removal suggests that the virus has been recognized as foreign and tagged for immune adherence and destruction. Opsonization by complement followed by uptake via the recently described CRIg provides a mechanistic explanation for these important observations made nearly five decades ago [66].
###end p 73
###begin p 74
###xml 629 633 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Earl1">[67]</xref>
###xml 634 638 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Jahrling1">[72]</xref>
###xml 519 532 <span type="species:ncbi:10255">variola virus</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
These observations influence the interpretation of poxviral infections initiated with an IMV-rich inoculum by the intravenous route. The liver's Kupffer cells may sequester most of the inoculated virus within minutes and destroy much of it within an hour, thereby inhibiting systemic dissemination. Not only is the dose effectively reduced by approximately10-fold, but the neutralized IMV also provides the immune system with an immediate source of antigen. These issues have particular relevance for the monkeypox and variola virus non-human primate models that commonly use the intravenous route to test vaccines for human use [67]-[72].
###end p 74
###begin p 75
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Mehlhop1">[23]</xref>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 497 501 <span type="species:ncbi:12643">ECTV</span>
The early mortality of the C3-/-, C4-/-, and FB-/- mice demonstrates an essential role for the classical and alternative pathways in the initial stages of poxvirus infection. Despite equivalent mortality levels, further analysis may reveal different functions for each complement pathway in vivo, as such differences exist in the immune response to other viruses [23]. The similarity between the in vivo mortality and in vitro serum neutralization experiments suggests that complement neutralizes ECTV and thereby limits its spread. Undoubtedly, complement deposition triggers other effector functions, such as recruiting inflammatory cells, promoting phagocytosis, and priming the adaptive immune response. The precise contribution of each of these to protection in vivo remains unexplored.
###end p 75
###begin p 76
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chen1">[46]</xref>
###xml 403 418 <span type="species:ncbi:10244">monkeypox virus</span>
However, these experiments establish that complement is essential to the immune response to poxviruses. It accounts for why the virus encodes a potent complement regulatory protein. A virus lacking this regulator would be at risk for greater host complement activity and attenuation. This is consistent with the theory that loss of this regulator contributes to the reduced virulence of some strains of monkeypox virus [46]. To conclude, the complement system is critical for slowing down viral spread and decreasing tissue titers and damage.
###end p 76
###begin title 77
Materials and Methods
###end title 77
###begin title 78
Virus Production
###end title 78
###begin p 79
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Earl3">[73]</xref>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chen2">[74]</xref>
###xml 30 34 <span type="species:ncbi:12643">ECTV</span>
###xml 53 59 <span type="species:ncbi:10090">murine</span>
###xml 197 217 <span type="species:ncbi:9534">African green monkey</span>
###xml 392 396 <span type="species:ncbi:9913">calf</span>
Plaque-purified Moscow strain ECTV was propagated in murine L929 cells. Intracellular mature viral stocks were purified through a sucrose cushion as described [73] and titrated on BS-C-1 cells, an African green monkey kidney cell line [74]. Both cell lines were cultured in Dulbecco's modified Eagle's media (DMEM, BioWhittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal calf serum (FCS, HyClone, Logan, UT), 2 mM L-glutamine, and antibiotics.
###end p 79
###begin title 80
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice 
###end title 80
###begin p 81
###xml 63 66 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Suresh1">[56]</xref>
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Circolo1">[75]</xref>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Matsumoto1">[76]</xref>
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Wu1">[77]</xref>
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Fischer1">[78]</xref>
###xml 222 226 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Kitamura1">[79]</xref>
###xml 287 290 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 290 294 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Botto1">[80]</xref>
###xml 349 352 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 352 356 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Xu2">[81]</xref>
###xml 413 416 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 424 427 423 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 442 449 441 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Kata</sup>
###xml 454 461 453 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Kata</sup>
###xml 438 461 437 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mbl1<sup>tm1Kata</sup> Mbl2<sup>tm1Kata</sup></italic>
###xml 512 515 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 522 525 521 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 550 551 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 554 555 553 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 562 563 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 548 563 547 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hc<sup>1</sup> H2<sup>d</sup> H2-T18<sup>c</sup></italic>
###xml 579 580 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 583 584 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 577 587 576 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hc<sup>0</sup> H2<sup>d</sup> H2</italic>
###xml 591 592 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 588 592 587 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T18<sup>c</sup></italic>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
The following strains on a C57BL/6 background were acquired: C3-/-[56],[75] and FB-/-[76],[77] from H. Molina, Washington University Medical School; C4-/-[78] from M. Carroll, Harvard Medical School; B cell-deficient muMT [79] from H. W. Virgin, Washington University Medical School; C1q-/-[80] from M. Botto, Imperial College School of Medicine; FD-/-[81] from Y. Xu, University of Alabama, Birmingham; and MBL A-/- x MBL C-/- (B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J) and wild-type from Jackson Laboratories. The C5+/+ and C5-/- C57BL/10 mice (B10.D2-Hc1 H2d H2-T18c/nSnJ, B10.D2-Hc0 H2d H2-T18c/oSnJ) were also obtained from Jackson Laboratories. Age-matched mice of both sexes were used in the footpad and ear pinna studies (6-11 weeks-old) and the muMT survival experiments (10-11 weeks-old). Male mice were used in the intranasal (8-12 weeks) and sera transfer (10-12 weeks) studies. Some wild-type and muMT mice used in the footpad studies were purchased from Jackson Laboratories. The rest of the mice were bred at Washington University in a specific pathogen-free facility. The animals were transported to the biohazard suite at Saint Louis University at least a week prior to infection. All experiments were performed following the animal care guidelines of the two institutions.
###end p 81
###begin title 82
In Vivo Studies
###end title 82
###begin p 83
###xml 244 245 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 247 248 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 708 712 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Buller2">[82]</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 36 40 <span type="species:ncbi:12643">ECTV</span>
###xml 197 201 <span type="species:ncbi:10090">Mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
Mice were inoculated with 10 microl ECTV diluted in PBS to the indicated dose using a 29 gauge insulin syringe into the ear pinna and hind footpad or a 20 microl pipettor for the intranasal route. Mice were anesthetized for inoculation using CO2/O2 for the footpad route and ketamine/xylazine for the ear pinna and intranasal routes. Individual mice were marked by ear punching or shaving. After infection and before sacrifice in the mortality studies, mice were manipulated only to obtain weights. Serum was collected from surviving animals at the end of the experiment. The survival curves include only animals that generated an antiviral antibody response, which was detected by ELISA in >95% of the mice [82]. In the passive transfer experiment, mice received intraperitoneally 1 ml of wild-type or muMT C57BL/6 sera on day -1 and 0.5 ml every two days starting on day 0.
###end p 83
###begin title 84
Tissue Titer
###end title 84
###begin p 85
###xml 342 346 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Chen2">[74]</xref>
Blood was collected via cardiac puncture. Spleen and liver tissues were harvested aseptically, frozen immediately on dry ice, and stored at -70degreesC. Tissues were homogenized in PBS-1% FCS to approximately10% (weight/vol) using 1 ml glass homogenizers. They were frozen and thawed three times, sonicated, and titrated on BS-C-1 monolayers [74].
###end p 85
###begin title 86
Viremia Analysis
###end title 86
###begin p 87
###xml 495 496 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
DNA was isolated from whole blood collected in EDTA microtainer tubes (BD, Franklin Lakes, NJ) using the High Pure PCR Template Preparation Kit (Roche). The kit's whole blood protocol was used with the following modifications. The 40 microl Proteinase K, 200 microl Binding Buffer, 150 microl PBS, and 50 microl of whole blood in EDTA were added sequentially and then vortexed. The incubation at 70degreesC was extended to 12 min. The sample was applied to the column by centrifugation at 8,000 g for 2 min and eluted in 50 microl.
###end p 87
###begin p 88
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000249-Parker3">[83]</xref>
###xml 186 216 186 216 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTAGAACGACGCCAGAAT AAGAATA, 5&#8242;</named-content>
###xml 241 271 241 271 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">(AGAAGATATCAGACGATCCACAATC, 5&#8242;</named-content>
Quantitative PCR was performed on viral DNA using Power SYBR Green PCR Master Mix on a 7500 Real Time PCR System (Applied Biosystems, Foster City, CA) [83]. The primers (10 pmol) SP028 (GTAGAACGACGCCAGAAT AAGAATA, 5' at 120627 bp) and SP029 (AGAAGATATCAGACGATCCACAATC, 5' at 120462 bp) were used to amplify 165 bp of gene EV107. The amplification product cloned into a plasmid vector (pGEM-T, Promega) was used as a standard to estimate copies of DNA/microl in blood. Three to four wells were used for each sample.
###end p 88
###begin title 89
Histology
###end title 89
###begin p 90
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin by the Digestive Diseases Research Core Center, Washington University. The number of inflammatory foci and the magnitude of tissue necrosis were evaluated in blinded samples. Inflammatory foci in a 10x visual field were counted for approximately7 fields/mouse liver.
###end p 90
###begin title 91
Liver Enzymes
###end title 91
###begin p 92
AST and ALT levels were measured in samples of frozen sera by the Department of Comparative Medicine at Saint Louis University using a standard clinical analyzer.
###end p 92
###begin title 93
Complement Neutralization Assay
###end title 93
###begin p 94
###xml 233 235 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 238 240 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 306 308 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 311 313 303 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 436 438 428 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 441 443 433 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 465 466 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 551 553 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 556 558 534 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:12643">ECTV</span>
Mouse EDTA plasma and sera were collected on ice from male C57BL/6 mice in microtainer tubes (BD), separated by centrifugation, and then pooled, aliquoted, and frozen at -70degreesC. Plasma and sera were diluted on ice into GVB+/- Ca++/Mg++ (#B102, B103, Complement Technology, Tyler, TX) or GVB without Ca++/Mg++, respectively, to 2x the desired final concentration (vol/vol). Purified ECTV was sonicated and diluted in PBS (without Ca++/Mg++) to approximately5x104 pfu/ml. A 1:10 dilution in the buffer used to dilute the complement source, GVB+/-Ca++/Mg++, produced a final concentration of approximately5 pfu/microl. An equal volume of virus (30 microlapproximately150 pfu) was added rapidly to the diluted complement at RT. Samples were vortexed, centrifuged for 5 sec, and incubated at 37degreesC for 60-90 min. Samples were diluted by addition of 700 microl of DMEM-2% FCS, vortexed, and applied to BS-C-1 monolayers in 6-well plates. After 1 hr, 3 ml/well of 37degreesC overlay media (1% carboxymethylcellulose in culture media) was added. After 3-5 days, the cells were fixed with 1 ml/well of an 11% formaldehyde/ 0.13% crystal violet/ 5% ethanol solution for over 1 hr, rinsed, and dried. The number of plaques was scored visually using a light box. The EDTA plasma or sera data were normalized to the buffer only control or heat-inactivated sera, respectively.
###end p 94
###begin title 95
Statistical Analysis
###end title 95
###begin p 96
All statistical analysis was performed using GraphPad Prism software version 5.01 (GraphPad Software, San Diego, CA). The survival curves were analyzed by the log-rank test. The Mann-Whitney test was used to determine the statistical significance of the viral titers, viremia, liver histology, and liver enzymes. Either 1-way ANOVA followed by Tukey multiple comparisons test or 2-way ANOVA was used for the analysis of the complement neutralization assays.
###end p 96
###begin title 97
Supporting Information
###end title 97
###begin p 98
###xml 361 363 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:12643">ECTV</span>
C3 deficiency promoted earlier dissemination to and increased viral titers in the target organs. C3-deficient and wild-type mice were infected with approximately700 pfu of ECTV via the ear pinna and sacrificed on day 2, 4, 7, or 10 post-infection. The viral titer of the spleen (A) and liver (B) was determined by direct plaque assay and is expressed as the log10 plaque forming units (PFU)/g tissue. The level of viral DNA in whole blood was measured using quantitative PCR (C). Mean viral titers+/-SEM or genome copies+/-SEM are plotted against time. The dotted line represents the limit of detection for the assay.
###end p 98
###begin p 99
(0.49 MB TIF)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin p 101
###xml 264 268 <span type="species:ncbi:10090">mice</span>
The authors thank Mr. Ed Hembrador for assaying virus infectivity, Dr. Grant Kolar for analysis of the histopathology, the Digestive Diseases Research Core Center for preparing the tissue samples, and colleagues for their generous gift of the complement-deficient mice. Additional thanks to Dr. Erin Mehlhop, Dr. Scott Parker, Ms. Christina Oberle, Ms. Jill Schriewer, Ms. Erin Touchette, and Dr. John Sagartz for technical advice and assistance; to Dr. Herbert Virgin IV, Dr. Michael Diamond, Dr. Wayne Yokoyama, Dr. Hector Molina, Dr. Ted Hansen, Ms. Kathy Liszewski, and Ms. Paula Bertram for suggestions on experimental design and data analysis, to Dr. Michael Diamond for critically reading this manuscript, and to Ms. Madonna Bogacki for secretarial and administrative assistance.
###end p 101
###begin title 102
References
###end title 102
###begin article-title 103
The looming threat of bioterrorism.
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monkeypox: An emerging zoonotic disease.
###end article-title 104
###begin article-title 105
Poxvirus tropism.
###end article-title 105
###begin article-title 106
###xml 0 8 <span type="species:ncbi:12643">Mousepox</span>
Mousepox.
###end article-title 106
###begin article-title 107
###xml 94 102 <span type="species:ncbi:12643">mousepox</span>
Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox.
###end article-title 107
###begin article-title 108
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection.
###end article-title 108
###begin article-title 109
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Antibodies and CD8+ T Cells are complementary and essential for natural resistance to a highly lethal cytopathic virus.
###end article-title 109
###begin article-title 110
Obligatory requirement for antibody in recovery from a primary poxvirus infection.
###end article-title 110
###begin article-title 111
A role for NKG2D in NK cell-mediated resistance to poxvirus disease.
###end article-title 111
###begin article-title 112
###xml 46 62 <span type="species:ncbi:12643">ectromelia virus</span>
Induction of natural killer cell responses by ectromelia virus controls infection.
###end article-title 112
###begin article-title 113
Type 1 and type 2 cytokines in antiviral defense.
###end article-title 113
###begin article-title 114
###xml 43 51 <span type="species:ncbi:12643">mousepox</span>
Importance of interferons in recovery from mousepox.
###end article-title 114
###begin article-title 115
Interferon function is not required for recovery from a secondary poxvirus infection.
###end article-title 115
###begin article-title 116
###xml 37 53 <span type="species:ncbi:12643">ectromelia virus</span>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Perforin is essential for control of ectromelia virus but not related poxviruses in mice.
###end article-title 116
###begin article-title 117
###xml 13 27 <span type="species:ncbi:12643">mousepox virus</span>
Virulence of mousepox virus is independent of serpin-mediated control of cellular cytotoxicity.
###end article-title 117
###begin article-title 118
Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.
###end article-title 118
###begin article-title 119
Emerging patterns in complement-mediated pathogen recognition.
###end article-title 119
###begin article-title 120
Complement: Central to innate immunity and bridging to adaptive responses.
###end article-title 120
###begin article-title 121
Complement: A unique innate immune sensor for danger signals.
###end article-title 121
###begin article-title 122
C4A deficiency and nonresponse to hepatitis B vaccination.
###end article-title 122
###begin article-title 123
Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection.
###end article-title 123
###begin article-title 124
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.
###end article-title 124
###begin article-title 125
###xml 36 51 <span type="species:ncbi:11082">West Nile virus</span>
Protective immune responses against West Nile virus are primed by distinct complement activation pathways.
###end article-title 125
###begin article-title 126
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 82 109 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections.
###end article-title 126
###begin article-title 127
The relevance of complement to virus biology.
###end article-title 127
###begin article-title 128
Virus complement evasion strategies.
###end article-title 128
###begin article-title 129
###xml 22 27 <span type="species:ncbi:9606">human</span>
Complement evasion by human pathogens.
###end article-title 129
###begin article-title 130
Lectin complement system and pattern recognition.
###end article-title 130
###begin article-title 131
###xml 58 63 <span type="species:ncbi:9606">human</span>
The central role of the alternative complement pathway in human disease.
###end article-title 131
###begin article-title 132
Anaphylatoxins and infectious and non-infectious inflammatory diseases.
###end article-title 132
###begin article-title 133
Role of complement in immune regulation and its exploitation by virus.
###end article-title 133
###begin article-title 134
The complement system in regulation of adaptive immunity.
###end article-title 134
###begin article-title 135
###xml 0 14 <span type="species:ncbi:10245">Vaccinia virus</span>
Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.
###end article-title 135
###begin article-title 136
'Complementing' viral infection: Mechanisms for evading innate immunity.
###end article-title 136
###begin article-title 137
Poxvirus immunomodulatory strategies: Current perspectives.
###end article-title 137
###begin article-title 138
Poxvirus immune modulators: Functional insights from animal models.
###end article-title 138
###begin article-title 139
Technical knockout: Understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes.
###end article-title 139
###begin article-title 140
Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens.
###end article-title 140
###begin article-title 141
Viral mimicry of cytokines, chemokines and their receptors.
###end article-title 141
###begin article-title 142
Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.
###end article-title 142
###begin article-title 143
###xml 0 13 <span type="species:ncbi:10255">Variola virus</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complement.
###end article-title 143
###begin article-title 144
###xml 71 85 <span type="species:ncbi:10245">vaccinia virus</span>
Inhibition of the complement cascade by the major secretory protein of vaccinia virus.
###end article-title 144
###begin article-title 145
###xml 58 63 <span type="species:ncbi:9606">human</span>
Evolutionary history of orthopoxvirus proteins similar to human complement regulators.
###end article-title 145
###begin article-title 146
###xml 0 8 <span type="species:ncbi:10255">Smallpox</span>
Smallpox inhibitor of complement enzymes (SPICE): Regulation of complement activation on cells and mechanism of its cellular attachment.
###end article-title 146
###begin article-title 147
Structure and regulatory profile of the monkeypox inhibitor of complement: Comparison to homologs in vaccinia and variola and evidence for dimer formation.
###end article-title 147
###begin article-title 148
###xml 30 45 <span type="species:ncbi:10244">monkeypox virus</span>
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin.
###end article-title 148
###begin article-title 149
###xml 4 16 <span type="species:ncbi:10243">cowpox virus</span>
###xml 40 54 <span type="species:ncbi:10245">vaccinia virus</span>
The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein.
###end article-title 149
###begin article-title 150
###xml 56 68 <span type="species:ncbi:10243">cowpox virus</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: Investigation of the role of host complement in poxvirus pathogenesis.
###end article-title 150
###begin article-title 151
###xml 36 44 <span type="species:ncbi:12643">mousepox</span>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Differential pathogenesis of lethal mousepox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen.
###end article-title 151
###begin article-title 152
"Homologous restriction" in complement lysis: Roles of membrane complement regulators.
###end article-title 152
###begin article-title 153
###xml 22 36 <span type="species:ncbi:10245">vaccinia virus</span>
Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes.
###end article-title 153
###begin article-title 154
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 59 67 <span type="species:ncbi:12643">mousepox</span>
Studies on the innate resistance of mice to infection with mousepox. II. Route of inoculation and resistance; and some observations on the inheritance of resistance.
###end article-title 154
###begin article-title 155
Protective T cell-independent antiviral antibody responses are dependent on complement.
###end article-title 155
###begin article-title 156
Humoral response to herpes simplex virus is complement-dependent.
###end article-title 156
###begin article-title 157
Cutting edge: Myeloid complement C3 enhances the humoral response to peripheral viral infection.
###end article-title 157
###begin article-title 158
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection.
###end article-title 158
###begin article-title 159
###xml 90 105 <span type="species:ncbi:11082">West Nile virus</span>
Complement activation is required for induction of a protective antibody response against West Nile virus infection.
###end article-title 159
###begin article-title 160
###xml 0 8 <span type="species:ncbi:12643">Mousepox</span>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 83 99 <span type="species:ncbi:12643">ectromelia virus</span>
Mousepox in inbred mice innately resistant or susceptible to lethal infection with ectromelia virus. II. Pathogenesis.
###end article-title 160
###begin article-title 161
###xml 0 8 <span type="species:ncbi:12643">Mousepox</span>
Mousepox.
###end article-title 161
###begin article-title 162
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.
###end article-title 162
###begin article-title 163
Control of early viral and bacterial distribution and disease by natural antibodies.
###end article-title 163
###begin article-title 164
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 24 35 <span type="species:ncbi:111938">gatekeepers</span>
Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection.
###end article-title 164
###begin article-title 165
###xml 54 68 <span type="species:ncbi:10245">vaccinia virus</span>
The formation and function of extracellular enveloped vaccinia virus.
###end article-title 165
###begin article-title 166
###xml 24 38 <span type="species:ncbi:10245">vaccinia virus</span>
Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.
###end article-title 166
###begin article-title 167
CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens.
###end article-title 167
###begin article-title 168
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 56 72 <span type="species:ncbi:12643">ectromelia virus</span>
The response of mice to large intravenous injections of ectromelia virus. I. The fate of injected virus.
###end article-title 168
###begin article-title 169
###xml 42 50 <span type="species:ncbi:10255">smallpox</span>
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
###end article-title 169
###begin article-title 170
###xml 0 8 <span type="species:ncbi:10255">Smallpox</span>
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
###end article-title 170
###begin article-title 171
###xml 87 101 <span type="species:ncbi:10245">vaccinia virus</span>
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
###end article-title 171
###begin article-title 172
###xml 7 21 <span type="species:ncbi:10245">vaccinia virus</span>
Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge.
###end article-title 172
###begin article-title 173
###xml 0 8 <span type="species:ncbi:10255">Smallpox</span>
###xml 88 103 <span type="species:ncbi:10244">monkeypox virus</span>
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.
###end article-title 173
###begin article-title 174
###xml 27 40 <span type="species:ncbi:10255">variola virus</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 95 103 <span type="species:ncbi:10255">smallpox</span>
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
###end article-title 174
###begin article-title 175
Generation of recombinant vaccinia viruses.
###end article-title 175
###begin article-title 176
###xml 26 42 <span type="species:ncbi:12643">ectromelia virus</span>
Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene.
###end article-title 176
###begin article-title 177
###xml 26 32 <span type="species:ncbi:10090">murine</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA.
###end article-title 177
###begin article-title 178
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Abrogation of the alternative complement pathway by targeted deletion of murine factor B.
###end article-title 178
###begin article-title 179
Membrane protein Crry maintains homeostasis of the complement system.
###end article-title 179
###begin article-title 180
Regulation of the B cell response to T-dependent antigens by classical pathway complement.
###end article-title 180
###begin article-title 181
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin [mu] chain gene.
###end article-title 181
###begin article-title 182
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.
###end article-title 182
###begin article-title 183
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Complement activation in factor D-deficient mice.
###end article-title 183
###begin article-title 184
###xml 84 92 <span type="species:ncbi:12643">mousepox</span>
Evaluation of an enzyme-linked immunosorbent assay for the detection of ectromelia (mousepox) antibody.
###end article-title 184
###begin article-title 185
###xml 58 66 <span type="species:ncbi:12643">mousepox</span>
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
###end article-title 185
###begin p 186
###xml 53 67 53 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLoS Pathogens</italic>
R. Mark Buller is a member of the editorial board of PLoS Pathogens.
###end p 186
###begin p 187
This work was supported by NIAID grant NOI-AI-15436 (RMB), contracts U54-AI-057169 (RMLB and EAM) and U54-AI-057160 (EAM and JPA) from the NIAID to the Midwestern Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (MRCE). Additional support was also provided by NIH T32 HL07317-Principles in Pulmonary Research and T32 GM07200-National Research Service Award, Medical Scientist (EAM), and the Digestive Diseases Research Core Center (grant P30 DK52574).
###end p 187

